This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not an approved drug | Marketed in most countries as a research chemical |
| Main literature language | Russian and English | Early reports concentrated in Russian journals |
| Typical stated purity | ≥95% by HPLC | Supplier declaration, seldom independently verified |
| Principal studied endpoint | Telomerase activity in vitro | Measured in cultured human cells |
| Reported administration routes | Subcutaneous, intranasal | Described in exploratory use reports |
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
Although the number of American teenagers who smoked cigarettes was steadily falling during the 2010s, the prevalence of electronic cigarette use was rising. As of 2019, there is no evidence linking the availability of electronic cigarettes to a decline in traditional smoking among youths. Public opinion has turned against electronic cigarettes and various state and local governments are seeking to restrict use. By the mid-2020s, tobacco product use of all types among teenagers was on the decline, a trend largely driven by falling e-cigarette demand. Bloomberg reported in 2019 that members of Generation Z were twice as likely as an average American to consume cannabis. About 1% of the number of legal marijuana consumers came this demographic cohort, and that number tripled in 2019. Generation Z is the first to be born into a time when the legalization of marijuana at the federal level is being seriously considered. As of 2019, cannabis is legal in 33 U.S. states as well as in Canada and Uruguay. Even though Generation Z may not think of cannabis as anything more than a controversial issue, there is mounting concern on its effects on human health. A survey of literature reveals that marijuana usage is linked to, among other things, impaired driving, higher risks of stroke, testicular cancer, memory loss, and certain mental illnesses, such as psychosis. Compared to those who do not use cannabis or those who start after they reach 16 years, people who start before that age suffer from reduced cognitive functioning and higher levels of impulsivity.
== Departments == Clinical Biochemistry Clinical Neurosciences Cambridge Centre for Brain Repair Neurology Unit Neurosurgery Wolfson Brain Imaging Centre Haematology Transfusion Medicine Diagnostics Development Unit Medical Genetics Medicine Anaesthesia Clinical Pharmacology Obstetrics and Gynaecology Oncology Paediatrics Psychiatry Brain Mapping Unit Developmental Psychiatry Public Health and Primary Care The Primary Care Unit Clinical Gerontology Radiology Surgery Orthopaedic Research
Carbonization, the complete pyrolysis of organic matter, which usually leaves a solid residue that consists mostly of elemental carbon. Methane pyrolysis, the direct conversion of methane to hydrogen fuel and separable solid carbon, sometimes using molten metal catalysts. Hydrous pyrolysis, in the presence of superheated water or steam, producing hydrogen and substantial atmospheric carbon dioxide. Dry distillation, as in the original production of sulfuric acid from sulfates. Destructive distillation, as in the manufacture of charcoal, coke and activated carbon. Charcoal burning, the production of charcoal. Tar production by destructive distillation of wood in tar kilns. Caramelization of sugars. High-temperature cooking processes such as roasting, frying, toasting, and grilling. Cracking of heavier hydrocarbons into lighter ones, as in oil refining. Thermal depolymerization, which breaks down plastics and other polymers into monomers and oligomers. Ceramization involving the formation of polymer derived ceramics from preceramic polymers under an inert atmosphere. Catagenesis, the natural conversion of buried organic matter to fossil fuels. Flash vacuum pyrolysis, used in organic synthesis.
Sources: en.wikipedia.org
Besides platformer gameplay, one of the game's most distinctive gameplay features is allowing to switch the player character's form to suit one's needs. The player begins the game as Maui, whose only means of self-defence is an insect-launching pistol that can launch several forms of bugs, some of them combined for greater effect. However, once the player reaches the second level, Maui transforms into Cold Shadow, his ninja alter ego, who defends himself with short-range attacks using a bo staff. Cold Shadow's staff is also primarily used to explore the level further, such as climbing a narrow tunnel. After the second level, the player can switch back and forth between Maui and Cold Shadow at will, provided he has enough ninja tokens for the transformation. The amount of ninja tokens Maui or Cold Shadow holds determines Cold Shadow's strength – who can then chain more and more attacks as his skill improves – when played as him in the SNES version. On Mega Drive, however, Maui needs to collect red ninja tokens instead, the amount of white tokens being useful for metamorphosis alone. Some levels of the game, however, prevent Maui from transforming at all, as Cold Shadow cannot bungee jump on vines, for example, which forces the player to use Maui throughout the level.
Commensal bacteria contribute to immune maturation, maintenance of epithelial barrier function, and induction of tolerogenic immune responses. Reduced microbial diversity and loss of certain bacterial taxa may impair oral tolerance and promote allergic sensitization. Short-chain fatty acids produced by intestinal bacteria may further support regulatory immune pathways and intestinal barrier integrity. Sensitization to food allergens may also occur through non-oral routes. Exposure to allergens through damaged skin, particularly in individuals with impaired skin barriers such as those with atopic dermatitis, may predispose to food allergy if oral tolerance has not yet been established. This has contributed to the hypothesis that the timing, route, and context of allergen exposure influence whether tolerance or allergic sensitization develops. Research into gastrointestinal immune mechanisms has influenced preventive approaches to food allergy. Early introduction of allergenic foods, including peanuts and eggs, during infancy has been associated in some populations with a reduced risk of food allergy, likely by promoting oral tolerance during critical periods of immune development.
The ending isotope of this chain is now known to be thallium-205. Some older sources give the final isotope as bismuth-209, but in 2003 it was discovered that it is very slightly radioactive, with a half-life of 2.01×1019 years. There are also non-transuranic decay chains of unstable isotopes of light elements, for example those of magnesium-28 and chlorine-39. On Earth, most of the starting isotopes of these chains before 1945 were generated by cosmic radiation. Since 1945, the testing and use of nuclear weapons has also released numerous radioactive fission products. Almost all such isotopes decay by either β− or β+ decay modes, changing from one element to another at the same atomic mass. The later daughter products in such a chain, being closer to beta-stability, generally have the longer half-lives.
Adropin is a protein encoded by the energy homeostasis-associated gene ENHO in humans and is highly conserved across mammals. The biological role of adropin was first described in mice by Andrew Butler's team. They identified it as a protein hormone (hepatokine) secreted from the liver, playing a role in obesity and energy homeostasis. The name "Adropin" is derived from the Latin words "aduro" (to set fire to) and "pinguis" (fat). Adropin is produced in various tissues, including the liver, brain, heart, and gastrointestinal tract. In animals, adropin regulates carbohydrate and lipid metabolism and influences endothelial function. Its expression in the liver is controlled by feeding status, macronutrient content, as well as by the biological clock. Liver adropin is upregulated by estrogen via the estrogen receptor alpha (ERα). In humans, lower levels of circulating adropin are linked to several medical conditions, including the metabolic syndrome, obesity, and inflammatory bowel disease. and inflammatory bowel disease. The brain exhibits the highest levels of adropin expression, In the brain, adropin has been shown to have a potential protective role against neurological disease, where it may play a protective role against neurological diseases, brain aging, cognitive decline, and acute ischemia. as well as following acute ischemia. The orphan G protein-coupled receptor GPR19 has been proposed as a receptor for adropin.
Sources: en.wikipedia.org
Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.
The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.
It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.